PARMAXPharmaceuticals
Parmax Pharma Ltd — Profit & Loss Statement
₹28.44
-9.12%
Parmax Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -0.13 Cr | 0.00 | -0.12 Cr | -0.12 Cr | — |
| Tax Rate For Calcs | 0.13 | 0.30 | 0.30 | 0.30 | — |
| Normalized EBITDA | 0.29 Cr | -3.32 Cr | 2.70 Cr | 2.99 Cr | — |
| Total Unusual Items | -1.07 Cr | 0.00 | -0.40 Cr | -0.40 Cr | — |
| Total Unusual Items Excluding Goodwill | -1.07 Cr | 0.00 | -0.40 Cr | -0.40 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | -2.09 Cr | -5.75 Cr | -0.10 Cr | 0.14 Cr | — |
| Reconciled Depreciation | 1.03 Cr | 1.71 Cr | 1.88 Cr | 1.93 Cr | — |
| Reconciled Cost Of Revenue | 21.54 Cr | 7.05 Cr | 8.83 Cr | 10.53 Cr | — |
| EBITDA | -0.78 Cr | -3.32 Cr | 2.31 Cr | 2.59 Cr | — |
| EBIT | -1.81 Cr | -5.03 Cr | 0.43 Cr | 0.66 Cr | — |
| Net Interest Income | -0.59 Cr | -0.62 Cr | -0.38 Cr | -0.36 Cr | — |
| Interest Expense | 0.59 Cr | 0.62 Cr | 0.38 Cr | 0.35 Cr | — |
| Normalized Income | -1.16 Cr | -5.75 Cr | 0.17 Cr | 0.42 Cr | — |
| Net Income From Continuing And Discontinued Operation | -2.09 Cr | -5.75 Cr | -0.10 Cr | 0.14 Cr | — |
| Total Expenses | 28.98 Cr | 16.14 Cr | 14.62 Cr | 17.22 Cr | — |
| Diluted NI Availto Com Stockholders | -2.09 Cr | -5.75 Cr | -0.10 Cr | 0.14 Cr | — |
| Net Income Common Stockholders | -2.09 Cr | -5.75 Cr | -0.10 Cr | 0.14 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -2.09 Cr | -5.75 Cr | -0.10 Cr | 0.14 Cr | — |
| Net Income Including Noncontrolling Interests | -2.09 Cr | -5.75 Cr | -0.10 Cr | 0.14 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | -2.09 Cr | -5.75 Cr | -0.10 Cr | 0.14 Cr | — |
| Tax Provision | -0.30 Cr | 0.09 Cr | 0.15 Cr | 0.16 Cr | — |
| Pretax Income | -2.40 Cr | -5.66 Cr | 0.05 Cr | 0.30 Cr | — |
| Other Non Operating Income Expenses | 0.04 Cr | 0.05 Cr | 0.02 Cr | 0.03 Cr | — |
| Special Income Charges | -1.07 Cr | 0.00 | -0.40 Cr | -0.40 Cr | — |
| Net Non Operating Interest Income Expense | -0.59 Cr | -0.62 Cr | -0.38 Cr | -0.36 Cr | — |
| Interest Expense Non Operating | 0.59 Cr | 0.62 Cr | 0.38 Cr | 0.35 Cr | — |
| Operating Income | -0.78 Cr | -5.08 Cr | 0.80 Cr | 1.03 Cr | — |
| Operating Expense | 7.45 Cr | 9.08 Cr | 5.79 Cr | 6.68 Cr | — |
| Other Operating Expenses | 3.43 Cr | 4.46 Cr | 0.21 Cr | 0.27 Cr | — |
| Depreciation And Amortization In Income Statement | 1.03 Cr | 1.71 Cr | 1.88 Cr | 1.93 Cr | — |
| Depreciation Income Statement | 1.03 Cr | 1.71 Cr | 1.88 Cr | 1.93 Cr | — |
| Gross Profit | 6.67 Cr | 4.00 Cr | 6.59 Cr | 7.72 Cr | — |
| Cost Of Revenue | 21.54 Cr | 7.05 Cr | 8.83 Cr | 10.53 Cr | — |
| Total Revenue | 28.20 Cr | 11.05 Cr | 15.42 Cr | 18.25 Cr | — |
| Operating Revenue | 28.20 Cr | 11.05 Cr | 15.42 Cr | 18.25 Cr | — |
| Basic EPS | — | -15.37 | -0.28 | 0.38 | 2.00 |
| Interest Income | — | 0.02 Cr | 0.02 Cr | 0.03 Cr | 0.06 Cr |
| Diluted Average Shares | — | 0.37 Cr | 0.37 Cr | 0.37 Cr | 0.37 Cr |
| Basic Average Shares | — | 0.37 Cr | 0.37 Cr | 0.37 Cr | 0.37 Cr |
| Diluted EPS | — | -15.37 | -0.28 | 0.38 | 2.00 |
| Other Special Charges | — | 0.03 Cr | — | — | — |
| Write Off | — | 0.40 Cr | 0.40 Cr | 0.40 Cr | 0.46 Cr |
| Total Other Finance Cost | — | 0.10 Cr | 0.02 Cr | 0.03 Cr | 0.01 Cr |
| Interest Income Non Operating | — | 0.02 Cr | 0.02 Cr | 0.03 Cr | 0.06 Cr |
| Amortization | — | 0.00 | — | — | — |
| Selling General And Administration | — | 0.68 Cr | 0.86 Cr | 0.93 Cr | 0.89 Cr |
| Selling And Marketing Expense | — | 0.17 Cr | 0.13 Cr | 0.18 Cr | 0.18 Cr |
| General And Administrative Expense | — | 0.51 Cr | 0.73 Cr | 0.75 Cr | 0.71 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Parmax Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.